nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

28.10.2016 | Reply

Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma

verfasst von: Federico Fallanca, Pierpaolo Alongi, Elena Incerti, Luigi Gianolli, Maria Picchio, Irfan Kayani, Jamshed B. Bomanji

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

Sir, …

Fallanca F, Alongi P, Incerti E, Gianolli L, Picchio M, Kayani I, et al. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Eur J Nucl Med Mol Imaging. 2016;43:1837–48.

Adams HJ, Kwee TC. Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Br J Haematol. 2016. doi:10.1111/bjh.14052.

Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol. 2015;170:185–191.CrossRef

Metser U, Mohan R, Beckley V, Moshonov H, Hodgson D, Murphy G. FDG PET/CT response assessment criteria for patients with Hodgkin’s and non-Hodgkin’s lymphoma at end of therapy: a multiparametric approach. Nucl Med Mol Imaging. 2016;50:46–53.CrossRef

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842.

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–1514.CrossRef

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104:1258–1265.

Titel: Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma
verfasst von: Federico Fallanca
Pierpaolo Alongi
Elena Incerti
Luigi Gianolli
Maria Picchio
Irfan Kayani
Jamshed B. Bomanji
Publikationsdatum: 28.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3554-7

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel

Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients

Do we need FDG-PET/CT to assess atherosclerosis?

Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer

Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma

Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma